Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.

about

Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.

Item

http://www.wikidata.org/entity/Q47225018

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Safety of first-line triple th ...... ylori eradication in children.

@en

Safety of first-line triple th ...... ylori eradication in children.

@nl

type

Item

label

Safety of first-line triple th ...... ylori eradication in children.

@en

Safety of first-line triple th ...... ylori eradication in children.

@nl

prefLabel

Safety of first-line triple th ...... ylori eradication in children.

@en

Safety of first-line triple th ...... ylori eradication in children.

@nl

P1476

Safety of first-line triple th ...... ylori eradication in children.

@en

P2093

Chika Kusano

http://www.w3.org/2001/XMLSchema#string

Hisatomo Ikehara

http://www.w3.org/2001/XMLSchema#string

Mitsuhiko Moriyama

http://www.w3.org/2001/XMLSchema#string

Takuji Gotoda

http://www.w3.org/2001/XMLSchema#string

P2860

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

Helicobacter pylori infection and the development of gastric cancer

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.

Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model

Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.

Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.

Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.

P304

718-724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00535-017-1406-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sho Suzuki

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29110085

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori